{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stromal",
            "NStudiesAvail": 430108,
            "NStudiesFound": 326,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 326,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cell therapy in addition to corticosteroid therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy",
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy",
                              "Corticosteroid therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01589549"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [
                              "Neptune"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "allogeneic mesenchymal stromal cell infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02387151"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [
                              "REDDSTAR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stromal cells in collagen scaffold"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509870"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [
                              "ARDS-MSC-205"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cell Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [
                              "MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican\u00ae (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.\n\nAt the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)",
                              "Patients in the control group will receive Certican\u00ae (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells + Everolimus",
                              "Everolimus + Tacrolimus"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02057965"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cells administered weekly for 4 weeks"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells (MSC) for infusion"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01090817"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01522716"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [
                              "START"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.",
                              "A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Biological: Plasma-Lyte A"
                        ],
                        "ArmGroupLabel": [
                              "Human Mesenchymal Stromal Cells (hMSCs)",
                              "Plasma-Lyte A (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Sepsis with pneumonia",
                              "Sepsis without pneumonia",
                              "Pneumonia without sepsis",
                              "Aspiration only",
                              "Other",
                              "Volume control",
                              "Pressure-regulated volume control",
                              "Other"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02097641"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02150551"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.\n\n2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02012153"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [
                              "SAIL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection",
                              "Intramuscular placebo injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Mesenchymal Stromal Cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Stromal Cell",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03042572"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [
                              "STAT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.",
                              "A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Mesenchymal Stromal Cells",
                              "Biological: Cell Reconstitution Media"
                        ],
                        "ArmGroupLabel": [
                              "Human Mesenchymal Stromal Cells",
                              "Cell Reconstitution Media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818854"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [
                              "ADSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02323789"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [
                              "PTC-UC-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.\n\nThe dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).\n\nSince three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal stromal cells (UC-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02032446"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "5\u00d710^6 AD-MSCs",
                              "20\u00d710^6 AD-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03461458"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.\n\nParticipants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.",
                              "Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion",
                              "Other: Normal Saline (Placebo) Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cells Infusion",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [
                              "SAMPSON-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 1.25-1.5 x 10^6 cells/kg with a maximal dose of 100 x 10^6 cells on days 1 and 3 after study enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Stromal Cell infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05286255"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The number of mesenchymal stromal cells reached after two culture expansion passages.",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell",
                              "Biological: Saline"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00644410"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03268603"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [
                              "STOD3"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.",
                              "Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Stratum A",
                              "Stratum B"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01061099"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [
                              "MSC-GvHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injections for a dose of 1 \u00b1 0.5 x 106 MSC/kg recipient body weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01764100"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02215811"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [
                              "MSC-cGvHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with newly diagnosed cGvHD receive primary treatment plus MSC:\n\nMSC+prednisone+cyclosporine;\nMSC+prednisone+tacrolimus;\nMSC+prednisone+mycophenolate mofetil.",
                              "Patients with newly diagnosed cGvHD receive primary treatment:\n\nPlacebo+prednisone+cyclosporine;\nPlacebo+prednisone+tacrolimus;\nPlacebo+prednisone+mycophenolate mofetil."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells (MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02291770"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC therapy for severe COVID-19 infection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04445454"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [
                              "PRISME"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cell (MSC) injections"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cell (MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02814864"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [
                              "MANUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).",
                              "Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC injections",
                              "Placebo injections"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03211793"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects in the S50 cohort will receive one injection of 50 million AMSCs.",
                              "Subjects in the S100 cohort will receive one injection of 100 million AMSCs.",
                              "Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.",
                              "Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "S50",
                              "S100",
                              "M50",
                              "M100"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02805855"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 \u00b5L at the low dose level.",
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 \u00b5L at the medium dose level.",
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 \u00b5L each at the high dose level."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic MSC",
                              "Biological: Allogeneic MSC",
                              "Biological: Allogeneic MSC"
                        ],
                        "ArmGroupLabel": [
                              "Low dose of allogeneic MSC",
                              "Medium dose of allogeneic MSC",
                              "High dose of allogeneic MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04626583"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three fixed doses of MSC approximately 48 hours apart.",
                              "Three fixed doses of placebo control approximately 48 hours apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [
                              "COSMOS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.",
                              "Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Bone marrow analyses",
                              "Other: Bone marrow analyses"
                        ],
                        "ArmGroupLabel": [
                              "Acute Myeloid Leukemia patients",
                              "Healthy donors"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03233074"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive up to 2 infusions of mesenchymal stem cells.",
                              "Patients will receive supportive care or treatment designated by their treating doctor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Supportive Care"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors",
                              "age-matched healthy donors"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "osteoarthritic donors",
                              "healthy donors"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01038596"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [
                              "CARE-SSc"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.",
                              "Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.",
                              "Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC",
                              "Biological: UCMSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "One infusion of UCMSC",
                              "Two infusions of UCMSC",
                              "Placebo infusions"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04356287"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [
                              "MISTIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04549285"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving regular respiratory distress treatment",
                              "Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (iExosomes)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608631"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03014219"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSC"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived mesenchymal stromal cell (BM-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04236479"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [
                              "EPIC/MSC/IBD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01659762"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienb\u00f6ck's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02646007"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cell Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04255147"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical-cord mesenchymal stromal cells (UC-MSCs)\n\nAllogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB\n\nArm 2a: single infusion group. UC-MSCs at 0 month\n\nArm 2b: double infusion group. UC-MSCs at 0 and 6 months",
                              "Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical-cord mesenchymal stromal cells",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical-cord mesenchymal stromal cells",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580695"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [
                              "MSC in OB"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01175655"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)",
                              "No intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02565459"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).",
                              "Placebo (saline) is given intravenously over a period of 20-40 min."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: the ATMP Protrans",
                              "Biological: the ATMP Protrans"
                        ],
                        "ArmGroupLabel": [
                              "Wharton's jelly derived mesenchymal stromal cells (Protrans)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05061030"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients receiving low dose",
                              "3 patients receiving medium dose",
                              "3 patients receiving high dose",
                              "6 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ProTrans",
                              "Drug: ProTrans",
                              "Drug: ProTrans"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Medium dose",
                              "High dose",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03973827"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow transplantation",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Sickle cell disease",
                              "Thalassemia major"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00957931"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [
                              "MSC-ROLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.",
                              "Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC treatment",
                              "Drug: Standard of Care",
                              "Drug: Standard of Care",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03917797"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [
                              "COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "Intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04467047"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Approximately 1x10E6 MSC/kg",
                              "Solution identical to experimental treatment, without the MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal cells",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04615429"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.",
                              "Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bronchoscopy",
                              "Procedure: Bronchoscopy"
                        ],
                        "ArmGroupLabel": [
                              "Valves plus cells",
                              "Valves plus saline"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01872624"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [
                              "CISS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02421484"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).",
                              "Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Interferon gamma (IFN\u03b3)-primed human bone marrow-derived mesenchymal stromal cells",
                              "Drug: Interferon gamma (IFN\u03b3)-primed human bone marrow-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Adult Population",
                              "Pediatric Population"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04328714"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Repair of cranial defects by tissue engineering"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Repair of cranial defects by tissue engineering"
                        ],
                        "ArmGroupLabel": [
                              "Repair of cranial defect"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01742260"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of \u03b3MSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of \u03b3MSCs at 5x106 cells/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Albuterol Sulfate",
                              "Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)",
                              "Drug: Prednisone"
                        ],
                        "ArmGroupLabel": [
                              "Infusion of \u03b3MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05035862"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue",
                              "Standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Surgery",
                              "Other: autologous iliac crest",
                              "Procedure: Surgery"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA and surgery",
                              "Autologous iliac crest and surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02230514"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenously-infused allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) in children with Osteogenesis Imperfecta Type III that will be infused at 0 months, 4 months, 8 months, 12 months, 16 months, and 20 months, after enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow-derived mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Children with OI receiving Bone marrow-derived MSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05559801"
                        ]
                  },
                  {
                        "Rank": 58,
                        "Acronym": [
                              "COVID_MSV"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline",
                              "Intravenous injection of 100 ml of saline containing no cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04361942"
                        ]
                  },
                  {
                        "Rank": 59,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)",
                              "No treatment."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02260375"
                        ]
                  },
                  {
                        "Rank": 60,
                        "Acronym": [
                              "EMMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.",
                              "Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MC-ALPHA",
                              "Drug: Placebo",
                              "Drug: XCEL-MC-ALPHA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A: XCEL-MC-ALPHA/Placebo",
                              "Treatment B: Placebo/XCEL-MC-ALPHA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02495766"
                        ]
                  },
                  {
                        "Rank": 61,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive standard islet transplantation.",
                              "Patients will receive MSCs together with standard islet transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02384018"
                        ]
                  },
                  {
                        "Rank": 62,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first three subjects (minimum) will receive four weekly infusions of MSCs.",
                              "If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.",
                              "If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSCs",
                              "Biological: Autologous MSCs",
                              "Biological: Autologous MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSC dose level 1",
                              "MSC dose level 2",
                              "MSC dose level 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03298399"
                        ]
                  },
                  {
                        "Rank": 63,
                        "Acronym": [
                              "MSCDTDFU"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day",
                              "Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day",
                              "Topical application of fitostimoline every other day"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: dac-MSCs",
                              "Drug: Fitostimoline",
                              "Other: MSCs",
                              "Drug: Fitostimoline",
                              "Drug: Fitostimoline"
                        ],
                        "ArmGroupLabel": [
                              "dac-MSCs and Fitostimoline",
                              "MSCs and Fitostimoline",
                              "Fitostimoline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02943486"
                        ]
                  },
                  {
                        "Rank": 64,
                        "Acronym": [
                              "IMPACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One dose of 6x10e6 cells/kg administered intravenously.",
                              "Placebo infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cord Tissue Mesenchymal Stromal Cells",
                              "Other: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04089579"
                        ]
                  },
                  {
                        "Rank": 65,
                        "Acronym": [
                              "MSC Secretome"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses of allogenic MSC eye drops will be assigned at the lowest dose level.",
                              "Escalating doses of allogenic MSC eye drops will be assigned at the medium dose level.",
                              "Escalating doses of allogenic MSC eye drops will be assigned at the high dose level."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Secretome Eye Drops",
                              "Biological: MSC Secretome Eye Drops",
                              "Biological: MSC Secretome Eye Drops"
                        ],
                        "ArmGroupLabel": [
                              "Low dose of allogenic MSC drops",
                              "Medium dose of allogenic MSC drops",
                              "High dose of allogenic MSC drops"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05204329"
                        ]
                  },
                  {
                        "Rank": 66,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03449069"
                        ]
                  },
                  {
                        "Rank": 67,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv",
                              "Placebo: consisting of a 5% DMSO-solution in isotonic solution",
                              "Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv",
                              "Placebo: consisting of a 5% DMSO-solution in isotonic solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Allogeneic MSC",
                              "Drug: Placebo",
                              "Genetic: Allogeneic MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC week 4 and 3 before LVRS2",
                              "Placebo week 4 and 3 before LVRS2",
                              "MSC week 12 and 11 before LVRS2",
                              "Placebo week 12 and 11 before LVRS2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04918706"
                        ]
                  },
                  {
                        "Rank": 68,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients received treatment of a stem cell coated fistula plug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC Fistula Plug"
                        ],
                        "ArmGroupLabel": [
                              "MSC Fistula plug: Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02807389"
                        ]
                  },
                  {
                        "Rank": 69,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Treatment Group"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02589119"
                        ]
                  },
                  {
                        "Rank": 70,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible patients will be treated, single treatment group, no placebo arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03220243"
                        ]
                  },
                  {
                        "Rank": 71,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids",
                              "MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(\u2264 1x10^9/l).\n\naccording to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Standard therapy of septic shock",
                              "Genetic: Mesenchymal stromal cells",
                              "Drug: Standard therapy of septic shock"
                        ],
                        "ArmGroupLabel": [
                              "Standard therapy of septic shock",
                              "Mesenchymal stromal cells+ standard therapy of septic shock"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849237"
                        ]
                  },
                  {
                        "Rank": 72,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Dose Level 1: Infusion of MSCs",
                              "Dose Level 2: Infusion of MSCs",
                              "Dose Level 3: Infusion of MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02359929"
                        ]
                  },
                  {
                        "Rank": 73,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors",
                              "Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors",
                              "Infusion of saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: adipose derived mesenchymal stromal cells",
                              "Drug: adipose derived mesenchymal stromal cells",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Infusion of 100 million ASC",
                              "Infusion of 200 million ASC",
                              "Infusion of placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04714801"
                        ]
                  },
                  {
                        "Rank": 74,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01306513"
                        ]
                  },
                  {
                        "Rank": 75,
                        "Acronym": [
                              "RACE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:\n\n25% reduction of the ongoing immunosuppressive treatment following the first administration;\n50% reduction of the ongoing immunosuppressive treatment following the second administration;\ninterruption of the ongoing immunosuppressive treatment following the third administration.\n\nIn the case that the hypothesis that P \u2265 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cord-blood mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04034316"
                        ]
                  },
                  {
                        "Rank": 76,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue",
                              "A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint",
                              "Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint"
                        ],
                        "ArmGroupLabel": [
                              "Enzymatic digestion group",
                              "Mechanical fragmentation group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04675359"
                        ]
                  },
                  {
                        "Rank": 77,
                        "Acronym": [
                              "MyStromalCell"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC",
                              "Biological: Saline"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01449032"
                        ]
                  },
                  {
                        "Rank": 78,
                        "Acronym": [
                              "STROMA-CoV2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord Wharton's jelly-derived human",
                              "Other: NaCl 0.9%"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "NaCl"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 79,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02055625"
                        ]
                  },
                  {
                        "Rank": 80,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive standard care.",
                              "Patients will receive standard care plus cell therapy.",
                              "Patients will receive standard care plus cell therapy.",
                              "Patients will receive standard care plus cell therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stromal cell-based therapy",
                              "Other: Mesenchymal stromal cell-based therapy",
                              "Other: Mesenchymal stromal cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "MSC - low dose (2.5x10\u02c67)",
                              "MSC - intermediate dose (5x10\u02c67)",
                              "MSC - high dose (10x10\u02c67)"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04525378"
                        ]
                  },
                  {
                        "Rank": 81,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow",
                              "Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03522545"
                        ]
                  },
                  {
                        "Rank": 82,
                        "Acronym": [
                              "CIRCA-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "25 million cells/unit dose (cumulative dose: 75 million MSCs)",
                              "50 million cells/unit dose (cumulative dose: 150 million MSCs)",
                              "up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Panel 1",
                              "Panel 2",
                              "Panel 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 83,
                        "Acronym": [
                              "CLT-OA1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee",
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee",
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord derived-mesenchymal stromal cells",
                              "Biological: umbilical cord derived-mesenchymal stromal cells",
                              "Biological: umbilical cord derived-mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "CLT low-dose",
                              "CLT medium-dose",
                              "CLT high-dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03810521"
                        ]
                  },
                  {
                        "Rank": 84,
                        "Acronym": [
                              "LYSYME"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived stromal cells intravenously injected"
                        ],
                        "ArmGroupLabel": [
                              "Adipose derived stromal cells intravenously injected"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04711200"
                        ]
                  },
                  {
                        "Rank": 85,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with sepsis and septic shock and received MSCs&standart therapy",
                              "20 patients with sepsis and septic shock and not received MSCs, only received standart therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Patients received MSCs",
                              "Patients not received MSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05283317"
                        ]
                  },
                  {
                        "Rank": 86,
                        "Acronym": [
                              "Lipo-Hip"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be treated with an intra-articular-ultrasound-guided injection of Micro-fragmented adipose tissue containing mesenchymal stromal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Micro-fragmented adipose tissue injection"
                        ],
                        "ArmGroupLabel": [
                              "MF-AT injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05465096"
                        ]
                  },
                  {
                        "Rank": 87,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MSC, 5\u00d710^7 cells, one injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RegStem"
                        ],
                        "ArmGroupLabel": [
                              "RegStem"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03007576"
                        ]
                  },
                  {
                        "Rank": 88,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC-KI-PL-204"
                        ],
                        "ArmGroupLabel": [
                              "Single arm: MSC administration to vocal fold scar"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04290182"
                        ]
                  },
                  {
                        "Rank": 89,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first 10 consecutive patients will all receive investigational product.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Open Label infusion of hCT-MSC",
                              "Randomized infusion of hCT-MSC",
                              "Randomized infusion of Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  },
                  {
                        "Rank": 90,
                        "Acronym": [
                              "AMSC-ALS-001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Multipotent MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03828123"
                        ]
                  },
                  {
                        "Rank": 91,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.",
                              "Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.",
                              "Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Ruxolitinib",
                              "Other: Cellular Therapy",
                              "Drug: Ruxolitinib",
                              "Other: Cellular Therapy",
                              "Drug: Ruxolitinib"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1 (ruxolitinib)",
                              "Arm 2 (ruxolitinib, lower dose ds-MSCs)",
                              "Arm 3 (ruxolitinib, higher dose ds-MSCs)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04744116"
                        ]
                  },
                  {
                        "Rank": 92,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04489732"
                        ]
                  },
                  {
                        "Rank": 93,
                        "Acronym": [
                              "ASSIST-CLAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks",
                              "Placebo product manufactured to look like MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone-marrow derived MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone-marrow derived MSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02709343"
                        ]
                  },
                  {
                        "Rank": 94,
                        "Acronym": [
                              "TEACH"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.",
                              "If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.",
                              "If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Donor-derived Mesenchymal Stromal Cells",
                              "Drug: alemtuzumab",
                              "Drug: belatacept",
                              "Drug: sirolimus",
                              "Drug: mycophenolate mofetil",
                              "Drug: mycophenolate acid",
                              "Drug: prednisone",
                              "Biological: Donor-derived Mesenchymal Stromal Cells",
                              "Drug: alemtuzumab",
                              "Drug: belatacept",
                              "Drug: sirolimus",
                              "Drug: mycophenolate mofetil",
                              "Drug: mycophenolate acid",
                              "Drug: prednisone",
                              "Biological: Donor-derived Mesenchymal Stromal Cells",
                              "Drug: alemtuzumab",
                              "Drug: belatacept",
                              "Drug: sirolimus",
                              "Drug: mycophenolate mofetil",
                              "Drug: mycophenolate acid",
                              "Drug: prednisone"
                        ],
                        "ArmGroupLabel": [
                              "MSCs 10^4 cells/kg+anti-rejection drugs",
                              "MSCs 10^5 cells/kg+anti-rejection drugs",
                              "MSCs 10^6 cells/kg+anti-rejection drugs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03504241"
                        ]
                  },
                  {
                        "Rank": 95,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one low dose of allogeneic A-MSC.",
                              "Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one high dose of allogeneic A-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)",
                              "Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Group",
                              "High Dose Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05456243"
                        ]
                  },
                  {
                        "Rank": 96,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366830"
                        ]
                  },
                  {
                        "Rank": 97,
                        "Acronym": [
                              "ENTRUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BPF-001"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04435249"
                        ]
                  },
                  {
                        "Rank": 98,
                        "Acronym": [
                              "RegenHeart"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1\u00d710 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy",
                              "Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cardiac catheterization",
                              "Biological: Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells",
                              "Procedure: Cardiac catheterization"
                        ],
                        "ArmGroupLabel": [
                              "Main Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04325594"
                        ]
                  },
                  {
                        "Rank": 99,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-CVU",
                              "Drug: Placebo",
                              "Biological: allo-APZ2-CVU",
                              "Biological: allo-APZ2-CVU"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm\u00b2)",
                              "Placebo",
                              "allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm\u00b2)",
                              "allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm\u00b2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04971161"
                        ]
                  },
                  {
                        "Rank": 100,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans\u00ae).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ProTrans\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04896853"
                        ]
                  },
                  {
                        "Rank": 101,
                        "Acronym": [
                              "MSC-AFP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible patients will be treated, single treatment group, no placebo arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03209700"
                        ]
                  },
                  {
                        "Rank": 102,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single infusion of 200 million cells per patient.",
                              "Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ProTrans: Allogeneic transplantation with WJMSCs",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic transplantation with WJMSCs",
                              "Sham transplantation (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03406585"
                        ]
                  },
                  {
                        "Rank": 103,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: allo-APZ2-OTS",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Verum",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05464381"
                        ]
                  },
                  {
                        "Rank": 104,
                        "Acronym": [
                              "Disc_allo"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline",
                              "Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic Mesenchymal Stromal Cells",
                              "Drug: Mepivacaine"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stromal Cells",
                              "Mepivacaine"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01860417"
                        ]
                  },
                  {
                        "Rank": 105,
                        "Acronym": [],
                        "AgreementOtherDetails": [
                              "Publications (abstracts, posters or presentations) must be presented to the Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Participants were treated with intravenous (IV) remestemcel-L at a dose of 2\u00d710^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2\u00d710^6 MSCs/kg actual body weight at Screening."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: remestemcel-L"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L 2\u00d710^6 MSCs/kg"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02336230"
                        ]
                  },
                  {
                        "Rank": 106,
                        "Acronym": [
                              "Merlin"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.",
                              "Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Orbcel-C",
                              "Biological: Orbcel-C"
                        ],
                        "ArmGroupLabel": [
                              "PSC patients",
                              "AiH patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02997878"
                        ]
                  },
                  {
                        "Rank": 107,
                        "Acronym": [
                              "MSV_allo"
                        ],
                        "AgreementOtherDetails": [
                              "The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.",
                              "Intraarticular injection of hyaluronic acid (60 mg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Allogenic mesenchymal stromal cells injection",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic mesenchymal stromal cells injection",
                              "Hyaluronic acid (Durolane)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 108,
                        "Acronym": [
                              "ProTrans19+"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous administration, 1 dose, for 20 minutes",
                              "Intravenous administration, 1 dose, for 20 minutes"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Wharton's jelly-MSCs (WJ-MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04869397"
                        ]
                  },
                  {
                        "Rank": 109,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03901235"
                        ]
                  },
                  {
                        "Rank": 110,
                        "Acronym": [
                              "SAMCIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset",
                              "Infusion of normal saline placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Infusion",
                              "Biological: Placebo Comparator"
                        ],
                        "ArmGroupLabel": [
                              "MSC infusion",
                              "SHAM infusion"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01922908"
                        ]
                  },
                  {
                        "Rank": 111,
                        "Acronym": [
                              "ASC COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million allogeneic adipose-derived mesenchymal stromal cell",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Stem Cell Product",
                              "Drug: Stem Cell Product"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 112,
                        "Acronym": [
                              "MSC-CY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Cyclophosphamide",
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC+CY"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02270307"
                        ]
                  },
                  {
                        "Rank": 113,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program",
                              "Standard rehabilitation program"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-M-ALPHA and standard rehabilitation",
                              "Other: Rehabilitation"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-M-ALPHA and standard rehabilitation",
                              "standard rehabilitation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02033525"
                        ]
                  },
                  {
                        "Rank": 114,
                        "Acronym": [
                              "CEL&VAL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Device: Zephyr Endobronchial Valve",
                              "Biological: Marrow-derived mesenchymal stromal cell",
                              "Device: Zephyr Endobronchial Valve"
                        ],
                        "ArmGroupLabel": [
                              "Endobronchial valve + marrow-derived mesenchymal stromal cell",
                              "Endobronchial valve"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 115,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)",
                              "Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05433298"
                        ]
                  },
                  {
                        "Rank": 116,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14",
                              "One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14",
                              "One time infusion of islets only."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSCs at 20x10^6",
                              "BM-MSCs at 50x10^6",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05095532"
                        ]
                  },
                  {
                        "Rank": 117,
                        "Acronym": [
                              "NEPHSTROM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived Mesenchymal Stromal Cells",
                              "Cryostor CS10"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02585622"
                        ]
                  },
                  {
                        "Rank": 118,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adult Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02165904"
                        ]
                  },
                  {
                        "Rank": 119,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)"
                        ],
                        "ArmGroupLabel": [
                              "5 million MSC",
                              "10 million MSC",
                              "15 million MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02603744"
                        ]
                  },
                  {
                        "Rank": 120,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: expanded autologous bone marrow derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04815213"
                        ]
                  },
                  {
                        "Rank": 121,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SBI-101 device containing 250 million MSCs",
                              "SBI-101 device containing 750 million MSCs",
                              "Sham device containing no MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SBI-101",
                              "Biological: SBI-101",
                              "Device: Sham"
                        ],
                        "ArmGroupLabel": [
                              "Low dose cohort",
                              "High dose cohort",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03015623"
                        ]
                  },
                  {
                        "Rank": 122,
                        "Acronym": [
                              "USPIO-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "USPIO labeled MSC injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: USPIO labeled MSC injection"
                        ],
                        "ArmGroupLabel": [
                              "USPIO labeled MSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03651791"
                        ]
                  },
                  {
                        "Rank": 123,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ELWB newborns who will receive intranasal exosomes",
                              "ELWB newborns who will not receive intranasal exosomes"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Exosomes derived from mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Intranasal exosomes administration",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05490173"
                        ]
                  },
                  {
                        "Rank": 124,
                        "Acronym": [
                              "MSCTPHSCT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients treated with mesenchymal stromal cell",
                              "Patients treated without mesenchymal stromal cell"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cell",
                              "non-mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05131412"
                        ]
                  },
                  {
                        "Rank": 125,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SBI-101 device containing 250 million MSCs",
                              "SBI-101 device containing 750 million MSCs",
                              "Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SBI-101",
                              "Biological: SBI-101"
                        ],
                        "ArmGroupLabel": [
                              "Low dose cohort",
                              "High dose cohort",
                              "Case controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04445220"
                        ]
                  },
                  {
                        "Rank": 126,
                        "Acronym": [
                              "NEC15"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Core decompression procedure"
                        ],
                        "ArmGroupLabel": [
                              "Hip avascular necrosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04210440"
                        ]
                  },
                  {
                        "Rank": 127,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04456439"
                        ]
                  },
                  {
                        "Rank": 128,
                        "Acronym": [
                              "IDUNN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.",
                              "Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MC0518",
                              "Biological: BAT"
                        ],
                        "ArmGroupLabel": [
                              "MC0518",
                              "Best Available Therapy (BAT)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04629833"
                        ]
                  },
                  {
                        "Rank": 129,
                        "Acronym": [
                              "ADIPOA-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.",
                              "Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.",
                              "0.5% glucose in saline with 4.5% albumin"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection (2x106 ASC/5ml).",
                              "Biological: Injection (10x106 ASC/5ml).",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "2x106 ASC intra-articular injection",
                              "10x106 ASC intra-articular injection",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02838069"
                        ]
                  },
                  {
                        "Rank": 130,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of remestemcel-L 2x10^6 MSC/kg of body weight plus standard of care",
                              "Placebo (Plasma-Lyte) plus standard of care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Remestemcel-L",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L Plus Standard of Care",
                              "Placebo Plus Standard of Care"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 131,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSGS who underwent intravenous injection of AD-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02382874"
                        ]
                  },
                  {
                        "Rank": 132,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.",
                              "The patients with nonunion fracture who underwent percutaneous injection of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Percutaneous injection",
                              "Other: Percutaneous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipients",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02448849"
                        ]
                  },
                  {
                        "Rank": 133,
                        "Acronym": [
                              "COMET20d"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Harvest"
                        ],
                        "ArmGroupLabel": [
                              "Healthy Volunteer"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04397471"
                        ]
                  },
                  {
                        "Rank": 134,
                        "Acronym": [
                              "TACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04294290"
                        ]
                  },
                  {
                        "Rank": 135,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection",
                              "Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Single Injection",
                              "Two Injections"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608579"
                        ]
                  },
                  {
                        "Rank": 136,
                        "Acronym": [
                              "MSC-AFP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01915927"
                        ]
                  },
                  {
                        "Rank": 137,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Peripheral blood stem cell mobilisation and collection",
                              "Drug: High-dose chemotherapy",
                              "Drug: Bone marrow derived allogeneic MMSCs infusion",
                              "Procedure: Autologous peripheral blood stem cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic MMSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145923"
                        ]
                  },
                  {
                        "Rank": 138,
                        "Acronym": [
                              "ACCeNT-CP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells",
                              "Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors",
                              "Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of allogeneic umbilical cord blood",
                              "Biological: Infusion of MSCs",
                              "Biological: Infusion of allogeneic umbilical cord blood"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Umbilical Cord Blood",
                              "Cord Tissue Mesenchymal Stromal Cells",
                              "Natural History"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03473301"
                        ]
                  },
                  {
                        "Rank": 139,
                        "Acronym": [
                              "CME-LEM1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01909154"
                        ]
                  },
                  {
                        "Rank": 140,
                        "Acronym": [
                              "AIMs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10^6 cells/kg with a maximum dose of 10 x 10^7 cells/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04484077"
                        ]
                  },
                  {
                        "Rank": 141,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02829216"
                        ]
                  },
                  {
                        "Rank": 142,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 MSCs",
                              "10 x 10^6 MSCs",
                              "50 x 10^6 MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 1 x 10^6 MSCs",
                              "Biological: 10 x 10^6 MSCs",
                              "Biological: 50 x 10^6 MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02351011"
                        ]
                  },
                  {
                        "Rank": 143,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00260338"
                        ]
                  },
                  {
                        "Rank": 144,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "REDUCED INTENSITY CONDITIONING (RIC):\n\nFlu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.\n\nFlu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.\n\nGVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.\n\nTRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: cyclophosphamide",
                              "Drug: fludarabine phosphate",
                              "Radiation: total-body irradiation",
                              "Drug: cyclosporine",
                              "Drug: mycophenolate mofetil",
                              "Procedure: umbilical cord blood transplantation",
                              "Procedure: mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (intra-osseous UCB with hMSC co-transplant)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02181478"
                        ]
                  },
                  {
                        "Rank": 145,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03389919"
                        ]
                  },
                  {
                        "Rank": 146,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing",
                              "Standard surgical treatment with isolated endomedullary nailing"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-BETA",
                              "Procedure: Surgical treatment",
                              "Procedure: Surgical treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-BETA",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02630836"
                        ]
                  },
                  {
                        "Rank": 147,
                        "Acronym": [
                              "hCT-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects 1-3 will receive a single infusion of hCT-MSCs.",
                              "Subjects 4-6 will receive two infusions of hCT-MSCs.",
                              "Subjects 6-12 will receive three infusions of hCT-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC infusion",
                              "Biological: hCT-MSC infusion",
                              "Biological: hCT-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "Single hCT-MSC infusion",
                              "Two hCT-MSC infusions",
                              "Three hCT-MSC infusions"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03099239"
                        ]
                  },
                  {
                        "Rank": 148,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 x 10E6 ASC intra-articular injection (5 ml)",
                              "10 x 10E6 ASC intra-articular injection (5 ml)",
                              "50 x 10E6 ASC intra-articular injection (5 ml)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use",
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use",
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01585857"
                        ]
                  },
                  {
                        "Rank": 149,
                        "Acronym": [
                              "ADSCs-BWs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging",
                              "All patients will be subjected to standard stepped treatment of burn wounds:\n\nInfusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;\nSystemic antibiotic therapy for preventing infectious complications;\nAdequate analgesia and sedation;\nDecompression necrotomy in the first 24 hours following the burn trauma;\nNecrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;\nAutologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASCs"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASCs",
                              "The standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03113747"
                        ]
                  },
                  {
                        "Rank": 150,
                        "Acronym": [
                              "HELP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will receive HMB002 infusion into the peritoneal cavity."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HMB002"
                        ],
                        "ArmGroupLabel": [
                              "HMB002"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05491135"
                        ]
                  },
                  {
                        "Rank": 151,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The group of patients receive allogeneic MSCs therapies."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells(MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "The MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02706132"
                        ]
                  },
                  {
                        "Rank": 152,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo \"button (pellet)\" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic transplant of BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04545307"
                        ]
                  },
                  {
                        "Rank": 153,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Aspiration",
                              "Diagnostic Test: Ultrasound Imaging of Salivary Glands",
                              "Other: Salivary Assay",
                              "Other: Quality of Life Instruments"
                        ],
                        "ArmGroupLabel": [
                              "Participants with Xerostomia"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04007081"
                        ]
                  },
                  {
                        "Rank": 154,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).\n\nMaximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ABMD-MSC"
                        ],
                        "ArmGroupLabel": [
                              "ABDM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 155,
                        "Acronym": [
                              "CIS/MSC08"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "Cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01275612"
                        ]
                  },
                  {
                        "Rank": 156,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.\n\nParticipants will be followed for up to 1 year for assessment of endpoints."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells (MSCs)",
                              "Biological: Extracorporeal photopheresis (ECP)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs + ECP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05333029"
                        ]
                  },
                  {
                        "Rank": 157,
                        "Acronym": [
                              "MSV_LE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid",
                              "Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells (MSC)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells (MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03673748"
                        ]
                  },
                  {
                        "Rank": 158,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single arm, pneumostem treated infants"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: pneumostem"
                        ],
                        "ArmGroupLabel": [
                              "pneumostem group"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02274428"
                        ]
                  },
                  {
                        "Rank": 159,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first cohort of three patients will receive a single dose in the first 48 postnatal hours.",
                              "If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of hCT-MSC",
                              "Biological: Infusion of hCT-MSC"
                        ],
                        "ArmGroupLabel": [
                              "First cohort of 3 subjects enrolled",
                              "Second cohort of 3 subjects enrolled"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03635450"
                        ]
                  },
                  {
                        "Rank": 160,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A qualified enrolled donor will have an aspirate bone marrow draw."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Aspirate"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01463475"
                        ]
                  },
                  {
                        "Rank": 161,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get no stem cell infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologus Mesenchymal Stem Cells",
                              "Allogeniec Mesenchymal Stem Cells",
                              "Control without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02409940"
                        ]
                  },
                  {
                        "Rank": 162,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with CKD who underwent intravenous injection of MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02195323"
                        ]
                  },
                  {
                        "Rank": 163,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Drug: Low Dose Mesenchymal Stem Cells ( MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03171194"
                        ]
                  },
                  {
                        "Rank": 164,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ultra filtration failure (UFF) underwent AD-MSC injection.",
                              "The patients with ultra filtration failure (UFF) underwent Placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection",
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02801890"
                        ]
                  },
                  {
                        "Rank": 165,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.9% physiological saline",
                              "Low dose allogeneic mesenchymal stem cells derived from adipose tissue",
                              "High dose allogeneic mesenchymal stem cells derived from adipose tissue"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebos",
                              "Drug: Low dose allogeneic mesenchymal stromal cells",
                              "Drug: High dose allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control arm",
                              "Low dose treatment arm",
                              "High dose treatment arm"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466007"
                        ]
                  },
                  {
                        "Rank": 166,
                        "Acronym": [
                              "PASSIoN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All (near-)term newborns \u226536 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03356821"
                        ]
                  },
                  {
                        "Rank": 167,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.\n\nBMAC application at the time of arthroscopic labral repair.",
                              "Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.\n\nNo BMAC application at the time of arthroscopic labral repair."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMAC"
                        ],
                        "ArmGroupLabel": [
                              "BMAC Application",
                              "No BMAC Application"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03909139"
                        ]
                  },
                  {
                        "Rank": 168,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02247973"
                        ]
                  },
                  {
                        "Rank": 169,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously.",
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells",
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1 mil/kg",
                              "Dose 10 mil/kg"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02940418"
                        ]
                  },
                  {
                        "Rank": 170,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Arterial infusion of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "infusion of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01840540"
                        ]
                  },
                  {
                        "Rank": 171,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Cotransplant with MSCs"
                        ],
                        "ArmGroupLabel": [
                              "HSC",
                              "MSC+HSC"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04247945"
                        ]
                  },
                  {
                        "Rank": 172,
                        "Acronym": [
                              "CISS2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Intravenous infusion of Placebo, with excipients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03369275"
                        ]
                  },
                  {
                        "Rank": 173,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.",
                              "Patients receive only standard of care drugs for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs)",
                              "Arm II (standard of care drugs)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02408432"
                        ]
                  },
                  {
                        "Rank": 174,
                        "Acronym": [
                              "ExoOA-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Exosomes (sEVs)"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group - sEVs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05060107"
                        ]
                  },
                  {
                        "Rank": 175,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity",
                              "Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MNC",
                              "Biological: MSC",
                              "Procedure: Control",
                              "Biological: MNC",
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MNC & MSC with Control",
                              "MNC & MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03795974"
                        ]
                  },
                  {
                        "Rank": 176,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single IV infusion of ULSC's in patients with DM or PM"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Lining Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04723303"
                        ]
                  },
                  {
                        "Rank": 177,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: ASC enriched lipofilling",
                              "Biological: Standard Lipofilling"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03258164"
                        ]
                  },
                  {
                        "Rank": 178,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive standard of care treatment for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs IV)",
                              "Arm II (hMSCs transendocardially)",
                              "Arm III (standard of care)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 179,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Metformin + Placebo.",
                              "Metformin + Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebos",
                              "Drug: Semaglutide"
                        ],
                        "ArmGroupLabel": [
                              "Group A Placebo",
                              "Group B Active"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04126603"
                        ]
                  },
                  {
                        "Rank": 180,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "'Ex vivo expanded cord blood cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Ex vivo expanded cord blood cells"
                        ],
                        "ArmGroupLabel": [
                              "Expanded"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01624701"
                        ]
                  },
                  {
                        "Rank": 181,
                        "Acronym": [
                              "TACTICAL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients",
                              "Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.\n\nPatients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care.",
                              "cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.\n\nPatients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: MSCTRAIL",
                              "Genetic: MSCTRAIL",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 - RP2D finding study",
                              "Phase 2 Intervention Arm",
                              "Phase 2 Control Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03298763"
                        ]
                  },
                  {
                        "Rank": 182,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Oral mucosa biopsy",
                              "Procedure: Sinus lift with implantation of tissue engineered construction",
                              "Device: Dental implant"
                        ],
                        "ArmGroupLabel": [
                              "Tissue engineered construction implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02209311"
                        ]
                  },
                  {
                        "Rank": 183,
                        "Acronym": [
                              "COVIDMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton-Jelly mesenchymal stromal cells on D1 and D3",
                              "Placebo on D1 and D3"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A",
                              "Treatment B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 184,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier"
                        ],
                        "ArmGroupLabel": [
                              "CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05553132"
                        ]
                  },
                  {
                        "Rank": 185,
                        "Acronym": [
                              "NurOwn"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration",
                              "Combined intramuscular and intrathecal placebo administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSC-NTF cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC-NTF cells",
                              "Excipient"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02017912"
                        ]
                  },
                  {
                        "Rank": 186,
                        "Acronym": [
                              "STREAMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1-2 x106 MSCs/kg administered at Week 0",
                              "Suspension media administered at Week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 187,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10^6 UC-MSCs",
                              "Intra-parenchymal transplantation of 20x10^6 UC-MSCs",
                              "Neurologic and Neutrophic Drugs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Procedure: Neurologic and Neutrophic Drugs"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment",
                              "Umbilical cord mesenchymal stem cells treatment",
                              "Standard treatment (control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05008588"
                        ]
                  },
                  {
                        "Rank": 188,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placebo",
                              "a single intravenous autologous bone marrow mononuclear cell transfusion",
                              "a single intravenous autologous marrow stromal cell transfusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: placebo",
                              "Biological: autologous bone marrow mononuclear cell transfusion",
                              "Biological: marrow stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "autologous mononuclear cells",
                              "autologous marrow stromal cells"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00908856"
                        ]
                  },
                  {
                        "Rank": 189,
                        "Acronym": [
                              "AMSC_UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "interventions: The MSCs of 5\u00d710*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week\uff0ca total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used",
                              "interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose-cord mesenchymal stromal cells (A-MSCs)",
                              "Other: Conventional drugs",
                              "Other: Conventional drugs"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03609905"
                        ]
                  },
                  {
                        "Rank": 190,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of 2\u00d710~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)",
                              "Intraarticular injection of hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs)",
                              "Other: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166865"
                        ]
                  },
                  {
                        "Rank": 191,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placenta Derived Mesenchymal Stem Cell administered into the knee joint once",
                              "Sodium hyaluronate administered into the knee joint once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta Derived Mesenchymal Stem Cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Placenta Derived Mesenchymal Stem Cell",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 192,
                        "Acronym": [
                              "MSCIMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: MSC Treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 193,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Early treatment with mesenchymal stem cells",
                              "Delayed treatment with mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 194,
                        "Acronym": [
                              "AMETHYST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single dose of GEM00220 at 15 million cells",
                              "Participants will receive a single dose of GEM00220 at 60 million cells",
                              "Participants will receive a single dose of GEM00220 at 150 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: GEM00220",
                              "Biological: GEM00220",
                              "Biological: GEM00220"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm - Low Dose",
                              "Treatment arm - Mid dose",
                              "Treatment arm - High dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04961658"
                        ]
                  },
                  {
                        "Rank": 195,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NurOwn (MSC-NTF cells)"
                        ],
                        "ArmGroupLabel": [
                              "NurOwn (MSC-NTF cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03799718"
                        ]
                  },
                  {
                        "Rank": 196,
                        "Acronym": [
                              "GVHD Cyto-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment",
                              "Placebo (normal saline) and standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03847844"
                        ]
                  },
                  {
                        "Rank": 197,
                        "Acronym": [
                              "CHAMP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.",
                              "Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.",
                              "Tissue Collection Group:\n\nAmputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation.",
                              "Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.",
                              "Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Active/Treatment Group",
                              "Observation Group 1",
                              "Observation Group 2",
                              "Observation Group 3",
                              "Control Group 4"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02685098"
                        ]
                  },
                  {
                        "Rank": 198,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2.5 x 10^6 MSC per kg will be infused intravenously on Day 1",
                              "Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)",
                              "Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)"
                        ],
                        "ArmGroupLabel": [
                              "Group A Treatment",
                              "Group B Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04061746"
                        ]
                  },
                  {
                        "Rank": 199,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three Intrathecal administrations of NurOwn\u00ae (MSC-NTF cells) at bi-monthly intervals",
                              "Three Intrathecal administrations of Placebo at bi-monthly intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NurOwn\u00ae (MSC-NTF cells)",
                              "Other: Bone Marrow aspiration",
                              "Other: Placebo",
                              "Other: Bone Marrow aspiration"
                        ],
                        "ArmGroupLabel": [
                              "NurOwn\u00ae (MSC-NTF cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03280056"
                        ]
                  },
                  {
                        "Rank": 200,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.",
                              "Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.",
                              "Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: umbilical cord blood mesenchymal stem cells",
                              "Drug: umbilical cord blood mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group MSC-1",
                              "Group MSC-2",
                              "Group Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02812121"
                        ]
                  },
                  {
                        "Rank": 201,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 202,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446640"
                        ]
                  },
                  {
                        "Rank": 203,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01305694"
                        ]
                  },
                  {
                        "Rank": 204,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 205,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .\n\nMSC a day-case 2\u00b70\u00d7106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v.",
                              "Patients with progressive and refractory NMO treated with regular methods"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 206,
                        "Acronym": [
                              "OLT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.",
                              "Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord",
                              "Procedure: Debridement and microfracture",
                              "Procedure: Debridement and microfracture"
                        ],
                        "ArmGroupLabel": [
                              "Debridement and microfracture in LOC + Cells",
                              "Debridement and microfracture in LOC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03905824"
                        ]
                  },
                  {
                        "Rank": 207,
                        "Acronym": [
                              "CIRCA-19 RCT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)",
                              "3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSCs Arm",
                              "Placebo Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04865107"
                        ]
                  },
                  {
                        "Rank": 208,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.",
                              "Subjects randomized to the placebo control group will undergo a \"sham\" bone marrow harvest."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous BMMNC Infusion",
                              "Biological: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BMMNC Infusion",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02525432"
                        ]
                  },
                  {
                        "Rank": 209,
                        "Acronym": [
                              "VIVAAA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.",
                              "In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.",
                              "In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs",
                              "Drug: Placebo",
                              "Biological: MSCs",
                              "Drug: Placebo",
                              "Biological: MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous infusion of 1 million allogenic MSC's/Kg",
                              "Intravenous infusion of 3 million allogeneic MSCs/kg",
                              "Intravenous infusion of Plasmalyte A (placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02846883"
                        ]
                  },
                  {
                        "Rank": 210,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biphasic phycogenic biomaterial and Autogenous cortical bone",
                              "Xenograft bovine hydroxyapatite and Autogenous cortical bone"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Biphasic phycogenic biomaterial",
                              "Device: Xenograft bovine hydroxyapatite"
                        ],
                        "ArmGroupLabel": [
                              "Biphasic phycogenic biomaterial",
                              "Xenograft bovine hydroxyapatite"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03682315"
                        ]
                  },
                  {
                        "Rank": 211,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After randomization, patients will be allocated to receive conventional treatment:\n\nBasiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.\nIf after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.",
                              "Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional treatment",
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "conventional treatment",
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02770430"
                        ]
                  },
                  {
                        "Rank": 212,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone",
                              "Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: PBM+ACB",
                              "Device: ABB+ACB"
                        ],
                        "ArmGroupLabel": [
                              "PBM+ACB",
                              "ABB+ACB"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03797963"
                        ]
                  },
                  {
                        "Rank": 213,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cell Therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cell Therapy"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152160"
                        ]
                  },
                  {
                        "Rank": 214,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02482194"
                        ]
                  },
                  {
                        "Rank": 215,
                        "Acronym": [
                              "COVID-19EXO2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants (n=30) in this group will receive standard therapy and exosomes of the first type.",
                              "Participants (n=30) in this group will receive standard therapy and exosomes of the second type.",
                              "Participants (n=30) in this group will receive standard therapy and inhalation placebo solution."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXO 1 inhalation",
                              "Drug: EXO 2 inhalation",
                              "Drug: Placebo inhalation"
                        ],
                        "ArmGroupLabel": [
                              "EXO-1",
                              "EXO-2",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04602442"
                        ]
                  },
                  {
                        "Rank": 216,
                        "Acronym": [
                              "COVID-19EXO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXO 1 inhalation",
                              "Drug: EXO 2 inhalation",
                              "Drug: Placebo inhalation"
                        ],
                        "ArmGroupLabel": [
                              "EXO-1",
                              "EXO-2",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003"
                        ],
                        "NCTId": [
                              "NCT04491240"
                        ]
                  },
                  {
                        "Rank": 217,
                        "Acronym": [
                              "IMPACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cartilage repair surgery"
                        ],
                        "ArmGroupLabel": [
                              "Cartilage repair surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02037204"
                        ]
                  },
                  {
                        "Rank": 218,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00731744"
                        ]
                  },
                  {
                        "Rank": 219,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.",
                              "The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later",
                              "The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.",
                              "The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Tranexamic Acid",
                              "Drug: Tranexamic Acid",
                              "Drug: Tranexamic Acid"
                        ],
                        "ArmGroupLabel": [
                              "The control group (Group K)",
                              "Group A, Tranexamic acid",
                              "Group B, autologous transfusion",
                              "Group C, alogenous transfusion"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator",
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03795649"
                        ]
                  },
                  {
                        "Rank": 220,
                        "Acronym": [
                              "MIFAML"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient newly diagnosed with AML in Saint Antoine hospital or Tours University hospital",
                              "Patient diagnosed with AML in Saint Antoine hospital in 2015 to 2019"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Patient newly diagnosed with AML (prospectively)",
                              "Patient diagnosed with AML (retrospectively)"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03918655"
                        ]
                  },
                  {
                        "Rank": 221,
                        "Acronym": [
                              "AURA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.",
                              "Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Microfracture",
                              "Device: Arthroscopic synovial brushing"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Intervention group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02696876"
                        ]
                  },
                  {
                        "Rank": 222,
                        "Acronym": [
                              "UCMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03745417"
                        ]
                  },
                  {
                        "Rank": 223,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose level 1 is 40 x 10^6",
                              "Dose level 2 is 160 x 10^6",
                              "RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19",
                              "Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19",
                              "Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Single agent RAPA-501 cells (dose level 1)",
                              "Single agent RAPA-501 cells (dose level 2)",
                              "RAPA-501 cells",
                              "Placebo-control Cohort"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04482699"
                        ]
                  },
                  {
                        "Rank": 224,
                        "Acronym": [
                              "ADMSP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4\uff0cweek 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265613"
                        ]
                  },
                  {
                        "Rank": 225,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs plus Calcipotriol ointment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03392311"
                        ]
                  },
                  {
                        "Rank": 226,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.\n\nThe basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Drug: PSORI-CM01 Granule",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04275024"
                        ]
                  },
                  {
                        "Rank": 227,
                        "Acronym": [
                              "ARTROCELL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.",
                              "Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.",
                              "Hyaluronic Acid 60mg/3ml administered intra-articularly."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous MSCs",
                              "Drug: Allogenic MSCs",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stromal Cells (MSC)",
                              "Allogenic Mesenchymal Stromal Cells (MSC)",
                              "Active Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05086939"
                        ]
                  },
                  {
                        "Rank": 228,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a single-group, open, investigator-initiated clinical study\n\n: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: autologous adipose derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "a single, open clinical trial"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02338271"
                        ]
                  },
                  {
                        "Rank": 229,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Consecutive patients receive intramedullary nail fixation with bone marrow concentration.",
                              "Previous age- and gender-matched patients who receive intramedullary nail fixation only."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: intramedullary nail fixation with bone marrow concentration",
                              "Other: intramedullary nail fixation"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Historical control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03794622"
                        ]
                  },
                  {
                        "Rank": 230,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration",
                              "Transforaminal lumbar interbody fusion with local bone graft"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration",
                              "Other: Transforaminal lumbar interbody fusion with local bone graft"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03793530"
                        ]
                  },
                  {
                        "Rank": 231,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive arthroscopic repair with bone marrow concentration.",
                              "The patients receive arthroscopic repair only"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: arthroscopic repair with bone marrow concentration",
                              "Other: arthroscopic repair"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Historical control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03792594"
                        ]
                  },
                  {
                        "Rank": 232,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive core decompression surgery with bone marrow concentration.",
                              "The previous age-, gender-, and stage-matched patients who received core decompression surgery only."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Core decompression surgery with bone marrow concentration",
                              "Other: Core decompression surgery"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Historical control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03787329"
                        ]
                  },
                  {
                        "Rank": 233,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: adipose derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "adipose derived stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02240823"
                        ]
                  },
                  {
                        "Rank": 234,
                        "Acronym": [
                              "DREAM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two procedures:\n\nBone marrow harvesting from the posterior superior iliac crest region\nSingle injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control",
                              "Two sham procedures:\n\nSimulated bone marrow harvesting without insertion into the posterior iliac crest region\nSimulated injection under only local anaesthesia without disc injection and without placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous BM-MSC",
                              "Procedure: Sham"
                        ],
                        "ArmGroupLabel": [
                              "Active Arm",
                              "Sham Procedure"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05066334"
                        ]
                  },
                  {
                        "Rank": 235,
                        "Acronym": [
                              "3-D-TEBE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with bone defects of critical size of long bones\n\n3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 3D-Tissue Engineered Bone Equivalent"
                        ],
                        "ArmGroupLabel": [
                              "3D-Tissue Engineered Bone Equivalent"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03103295"
                        ]
                  },
                  {
                        "Rank": 236,
                        "Acronym": [
                              "ACTIVE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two interventions:\n\nBone marrow harvesting from the posterior superior iliac crest region\nSingle injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control",
                              "Two sham procedures:\n\nSimulated bone marrow harvesting without insertion into the posterior iliac crest region\nSimulated injection under only local anaesthesia without disc injection, without placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous BM-MSC",
                              "Other: Sham Procedure"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BM-MSC injection",
                              "Sham Procedure"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04759105"
                        ]
                  },
                  {
                        "Rank": 237,
                        "Acronym": [
                              "PAG"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "biopsy of periodontal granulation tissue (surgical waste)",
                              "biopsy of periodontal granulation tissue (surgical waste)",
                              "necessitating an extraction of wisdom teeth"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: flow cytometry",
                              "Other: flow cytometry",
                              "Other: flow cytometry"
                        ],
                        "ArmGroupLabel": [
                              "chronic periodontitis",
                              "aggressive periodontitis (AP)",
                              "controls"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01993368"
                        ]
                  },
                  {
                        "Rank": 238,
                        "Acronym": [
                              "EMPHA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03369457"
                        ]
                  },
                  {
                        "Rank": 239,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fisetin 20 mg/kg/day, orally for 2 consecutive days",
                              "Placebo capsules orally for 2 consecutive days"
                        ],
                        "ArmGroupInterventionName": [
                              "Dietary Supplement: Fisetin",
                              "Drug: Placebo oral capsule"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03325322"
                        ]
                  },
                  {
                        "Rank": 240,
                        "Acronym": [
                              "PFCD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519671"
                        ]
                  },
                  {
                        "Rank": 241,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 2 times 106 MSC/kg for up to 12 doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02379442"
                        ]
                  },
                  {
                        "Rank": 242,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Pre-filled syringe with 4 \u00b1 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.",
                              "Pre-filled syringe with 4 \u00b1 1 mL containing a balanced saline solution supplemented with human albumin"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: WJ-MSC (XCEL-UMC-BETA)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC (XCEL-UMC-BETA)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05054803"
                        ]
                  },
                  {
                        "Rank": 243,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nPSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs.",
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nGu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PSORI-CM01 formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells",
                              "Drug: Gu Ben Hua Yu formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "PSORI-CM01 group",
                              "Gu Ben Hua Yu group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04785027"
                        ]
                  },
                  {
                        "Rank": 244,
                        "Acronym": [
                              "MFAT-SCI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg [triamcinolone acetonide]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.",
                              "Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Dexamethasone",
                              "Device: Lipogems"
                        ],
                        "ArmGroupLabel": [
                              "Corticosteroid",
                              "Micro-Fragmented Adipose Tissue"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04136743"
                        ]
                  },
                  {
                        "Rank": 245,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.",
                              "Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Lipogems",
                              "Drug: Normal Saline"
                        ],
                        "ArmGroupLabel": [
                              "Micro-Fragmented Adipose Tissue",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04274543"
                        ]
                  },
                  {
                        "Rank": 246,
                        "Acronym": [
                              "MESRIX-SAFETY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with intra-glandular Injections of allogeneic adipose derived stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose derived stem/stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic mesenchymal stem/stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03874572"
                        ]
                  },
                  {
                        "Rank": 247,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular administration in early stage patients",
                              "Intrathecal administration in progressive stage patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC-NTF cells transplantation (IM)",
                              "Biological: MSC-NTF cells transplantation (IT)"
                        ],
                        "ArmGroupLabel": [
                              "MSC-NTF cells IM",
                              "MSC-NTF cells IT"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01051882"
                        ]
                  },
                  {
                        "Rank": 248,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day \"1\", Day \"4\", Day \"7\".",
                              "Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 249,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: \"Health and Anemia\" study [Haematologica 2010;95:1849], and \"Monzino 80-plus\" study [BMC Neurol.2011;11:54, validation cohort]. Overall in 5000 subjects aged >65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations.",
                              "The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.\n\nThe investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value.",
                              "The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Clonal hematopoiesis (AIM 1)",
                              "Innovative predictive models in MDS (AIM2)",
                              "Predictive biomarkers in MDS (AIM3)"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04174547"
                        ]
                  },
                  {
                        "Rank": 250,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05187936"
                        ]
                  },
                  {
                        "Rank": 251,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia",
                              "2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03876197"
                        ]
                  },
                  {
                        "Rank": 252,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Lipogems"
                        ],
                        "ArmGroupLabel": [
                              "Lipogems"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03555773"
                        ]
                  },
                  {
                        "Rank": 253,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers",
                              "Intramuscular implantation of Autologous bone marrow-derived mononuclear cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of Autologous Bone Marrow Mononuclear Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Stem Cell Injection"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02619734"
                        ]
                  },
                  {
                        "Rank": 254,
                        "Acronym": [
                              "MEMBRAN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04883502"
                        ]
                  },
                  {
                        "Rank": 255,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.",
                              "Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions",
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Dose Arm 1",
                              "Dose Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04869761"
                        ]
                  },
                  {
                        "Rank": 256,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.",
                              "10x10^6 MSC",
                              "30x10^6 MSC",
                              "90x10^6 MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection."
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01144962"
                        ]
                  },
                  {
                        "Rank": 257,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems\u00ae system."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous micro-fragmented adipose tissue",
                              "Device: Lipogems system"
                        ],
                        "ArmGroupLabel": [
                              "Autologous micro-fragmented adipose tissue"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03167138"
                        ]
                  },
                  {
                        "Rank": 258,
                        "Acronym": [
                              "AVN-13"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)",
                              "core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: core decompression",
                              "Procedure: core decompression"
                        ],
                        "ArmGroupLabel": [
                              "Demineralized Bone Marrow (DBM)",
                              "Lyophilized Bone Chips (LBC)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01892514"
                        ]
                  },
                  {
                        "Rank": 259,
                        "Acronym": [
                              "MOUV-GOPRO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The study will be conducted in 4 visits:\n\na pre-inclusion visit during a routine care consultation where the patient will be informed about the study\na V1 inclusion visit (pre-surgery of the knee) during which informed consent, clinical examination, VAS, self-questionnaires, DXA, X-SENS sensor, MRI, isokinetism will be collected\na V2 visit during the operation, during which biological samples will be taken (muscle biopsy and collection of osteoarticular parts)\na V3 visit at 12 months with a clinical examination, EVA, self-questionnaires, DXA, isokinetics, X-SENS sensor, and collection of adverse events."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: X-sens sensor"
                        ],
                        "ArmGroupLabel": [
                              "total knee replacement surgery group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05488093"
                        ]
                  },
                  {
                        "Rank": 260,
                        "Acronym": [
                              "RanoKure"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.",
                              "Conventional endodontic procedure"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Regenerative Endodontic Procedure",
                              "Procedure: Conventional Root Canal Treatment"
                        ],
                        "ArmGroupLabel": [
                              "Regenerative Endodontic Procedure (REP)",
                              "Conventional Root Canal Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT03102879"
                        ]
                  },
                  {
                        "Rank": 261,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow stem cell implantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous bone marrow stem cell graft"
                        ],
                        "ArmGroupLabel": [
                              "Autologous bone marrow stem cell graft"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02448121"
                        ]
                  },
                  {
                        "Rank": 262,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF"
                        ],
                        "ArmGroupLabel": [
                              "MSC-NTF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01777646"
                        ]
                  },
                  {
                        "Rank": 263,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection",
                              "The patients who are in control group and underwent placebo injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03164083"
                        ]
                  },
                  {
                        "Rank": 264,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.",
                              "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose",
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose"
                        ],
                        "ArmGroupLabel": [
                              "Lower Dose MSC",
                              "Higher Dose MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03840343"
                        ]
                  },
                  {
                        "Rank": 265,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Biological: Bone marrow-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic Acid (HA) + P-MMSCs",
                              "Hyaluronic Acid (HA) + BM-MMSCs",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04453111"
                        ]
                  },
                  {
                        "Rank": 266,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: standard frailty treatment and supplementary medication",
                              "Drug: standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04919135"
                        ]
                  },
                  {
                        "Rank": 267,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.",
                              "To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation",
                              "Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived stem/stromal cells",
                              "Daily 2000 UI of daily oral cholecalciferol"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03920397"
                        ]
                  },
                  {
                        "Rank": 268,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year",
                              "400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Reference therapy: 400 mL of 0.9% NaCl solution"
                        ],
                        "ArmGroupLabel": [
                              "MSC group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849159"
                        ]
                  },
                  {
                        "Rank": 269,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection\n\nOther Names:\n\nADSC, mesenchymal cells, stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose derived mesenchymal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02326935"
                        ]
                  },
                  {
                        "Rank": 270,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly",
                              "One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Stromal Vascular Fraction (SVF)",
                              "Biological: Autologous Adipose Derieved MSCs",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Stromal Vascular Fraction",
                              "Autologous Adipose Derived MSCs",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145897"
                        ]
                  },
                  {
                        "Rank": 271,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Marrow stromal cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00186914"
                        ]
                  },
                  {
                        "Rank": 272,
                        "Acronym": [
                              "MILES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).",
                              "Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).",
                              "Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.",
                              "Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Biological: Adipose-derived MSCs",
                              "Biological: Umbilical Cord Tissue (UCT) MSCs",
                              "Drug: Corticosteroid injection"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Derived MSCs",
                              "Adipose-derived MSCs",
                              "Umbilical Cord Tissue (UCT) MSCs",
                              "Corticosteroid Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818737"
                        ]
                  },
                  {
                        "Rank": 273,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "taking umbilical cord derived mesenchymal stem cells",
                              "taking stromal vascular fraction cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells",
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord derived mesenchymal stem cells transplantation group",
                              "stromal vascular fraction cells application group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05305833"
                        ]
                  },
                  {
                        "Rank": 274,
                        "Acronym": [
                              "ASC-OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04223622"
                        ]
                  },
                  {
                        "Rank": 275,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.\n\nSubjects with uremia in the intervention group will undergo puncture to collect SVF\nSVF will be cultured to abstain MSC\nThe abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD.",
                              "induction with Basiliximab during kidney transplantation from DCD"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: SVFderived MSC transplantations",
                              "Drug: Basiliximab"
                        ],
                        "ArmGroupLabel": [
                              "SVF(Stromal Vascular Fraction) derived MSC transprlantation",
                              "Basiliximab"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02492490"
                        ]
                  },
                  {
                        "Rank": 276,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow mesenchymal stem cells 10 cc by intra articular injection once",
                              "Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once",
                              "Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow mesenchymal stem cells",
                              "Biological: Adipose Mesenchymal stem cells",
                              "Biological: bone marrow & adipose mesenchymal stem cells injection"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow mesenchymal stem cell",
                              "adipose mesenchymal stem cells",
                              "Bone marrow and Adipose mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04351932"
                        ]
                  },
                  {
                        "Rank": 277,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of autologous bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00781872"
                        ]
                  },
                  {
                        "Rank": 278,
                        "Acronym": [
                              "MYSTEP1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two doses of 1 x 10^6 MSCs/kg body weight:\n\nfirst administration intraoperatively via intraportal infusion\nsecond infusion via intravenous infusion on postoperative day 2 (+/- 1 day)\n\nStandard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02957552"
                        ]
                  },
                  {
                        "Rank": 279,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure",
                              "drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: drug therapy according to Vietnamese MOHS procedure",
                              "Drug: drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04433104"
                        ]
                  },
                  {
                        "Rank": 280,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.",
                              "This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Linagliptin",
                              "Drug: Linagliptin"
                        ],
                        "ArmGroupLabel": [
                              "Linagliptin patients with schizophrenia",
                              "Linagliptin control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02442817"
                        ]
                  },
                  {
                        "Rank": 281,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.",
                              "3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.",
                              "corticosteroids i.e. Prednisolone \u226410mg/day or \u226420 mg every alternate day\nImmunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day\nAntioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.\nPirfenidone at dose upto 1200 to 1800 mg/day"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Stromal Vascular Fraction (SVF)",
                              "Biological: Autologous Adipose Derived MSCs (ADMSCs)",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Stromal Vascular Fraction",
                              "Autologous Adipose Derived MSCs",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02135380"
                        ]
                  },
                  {
                        "Rank": 282,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.",
                              "Standard Conventional Treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose Tissue derived Total-Stromal-Cells (TOST)"
                        ],
                        "ArmGroupLabel": [
                              "Adipose Tissue derived Total-Stromal-Cells (TOST)",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05280002"
                        ]
                  },
                  {
                        "Rank": 283,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Repeated MSCs treatment in ALS patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04821479"
                        ]
                  },
                  {
                        "Rank": 284,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of autologous stromal vascular fraction on hand."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: injection of autologous stromal vascular fraction"
                        ],
                        "ArmGroupLabel": [
                              "Stromal vascular fraction injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02975960"
                        ]
                  },
                  {
                        "Rank": 285,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02749448"
                        ]
                  },
                  {
                        "Rank": 286,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Osteoarthritis A total of 140 patients ( May 2016 to june 2020) were treated with intra articular adipose derived stromal cells (ADSC)) also known as Stromal vascualr fraction administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose tissue derived stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05484856"
                        ]
                  },
                  {
                        "Rank": 287,
                        "Acronym": [
                              "HULPCIR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intralesional application"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose-derived stem cells without expanded"
                        ],
                        "ArmGroupLabel": [
                              "Autologous SVF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01548092"
                        ]
                  },
                  {
                        "Rank": 288,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose tissue derived stromal vascular fraction (SVF)"
                        ],
                        "ArmGroupLabel": [
                              "Patients with nonunion of long bones"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04340284"
                        ]
                  },
                  {
                        "Rank": 289,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 290,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.5 million (M) PLX-PAD cells per kg body weight",
                              "1.0 million (M) PLX-PAD cells per kg body weight",
                              "2.0 million (M) PLX-PAD cells per kg body weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PLX-PAD",
                              "Drug: PLX-PAD",
                              "Drug: PLX-PAD"
                        ],
                        "ArmGroupLabel": [
                              "0.5 M PLX-PAD",
                              "1 M PLX-PAD",
                              "2 M PLX-PAD"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01795950"
                        ]
                  },
                  {
                        "Rank": 291,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: adipose tissue derived stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue derived stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00913289"
                        ]
                  },
                  {
                        "Rank": 292,
                        "Acronym": [
                              "DMT1-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "DMT1+MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02893306"
                        ]
                  },
                  {
                        "Rank": 293,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.",
                              "Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
                              "Drug: Lactated Ringer's Solution"
                        ],
                        "ArmGroupLabel": [
                              "Experimental: Human (aMBMC)",
                              "Placebo:Lactated Ringer's Solution (LRS)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Class II",
                              "Class III"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02467387"
                        ]
                  },
                  {
                        "Rank": 294,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: adipose tissue derived stromal cells dosage"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue derived stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01062750"
                        ]
                  },
                  {
                        "Rank": 295,
                        "Acronym": [
                              "StemCell&CKD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants having a harvested total \"Adipose Derived Stem Cell (ADSC)\" count (in 5 ml SVF solution) more than 1 x 10^6.\n\nGenetic: SVF containing Autologous Non Expanded ADSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SVF Containg Autologous Non Expanded ADSC"
                        ],
                        "ArmGroupLabel": [
                              "Group A"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03939741"
                        ]
                  },
                  {
                        "Rank": 296,
                        "Acronym": [
                              "LECSINGST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.",
                              "LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: laparoscopic surgery",
                              "Procedure: laparoscopic and endoscopic cooperative surgery"
                        ],
                        "ArmGroupLabel": [
                              "laparoscopic surgery",
                              "laparoscopic and endoscopic combined surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03601234"
                        ]
                  },
                  {
                        "Rank": 297,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: adipose tissue derived stromal cells dosage"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue derived stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01709279"
                        ]
                  },
                  {
                        "Rank": 298,
                        "Acronym": [
                              "2ABC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous ADSC injection combined with laser therapy of the skin.",
                              "Normal sline injection combined with laser therapy of the skin."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laser therapy",
                              "Biological: Autologous ADSC injection",
                              "Procedure: Laser therapy",
                              "Procedure: Normal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose derived stem cells",
                              "Placebo - Normal saline injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03887208"
                        ]
                  },
                  {
                        "Rank": 299,
                        "Acronym": [
                              "REALIST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins",
                              "Plasma-Lyte 148 infused over 30 to 90 mins"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord derived CD362 enriched MSCs",
                              "Biological: Placebo (Plasma-Lyte 148)"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord derived CD362 enriched MSCs",
                              "Placebo (Plasma-Lyte 148) infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03042143"
                        ]
                  },
                  {
                        "Rank": 300,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).",
                              "In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.",
                              "Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: DNA extraction of tumer tissue samples and high-throughput sequencing of small panels",
                              "Other: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels",
                              "Other: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels"
                        ],
                        "ArmGroupLabel": [
                              "The construction of Gene detection technology flow",
                              "Establishment of non-invasive gene testing technology process",
                              "Prospective cohort (double-blind recommended)"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04143048"
                        ]
                  },
                  {
                        "Rank": 301,
                        "Acronym": [
                              "RESCeCUF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)",
                              "9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)",
                              "12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Stromal Vascular fraction",
                              "Autologous mesenchymal stem cells",
                              "Allogenic mesenchymal stem cells"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03726255"
                        ]
                  },
                  {
                        "Rank": 302,
                        "Acronym": [
                              "AMETIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Genetic: Autologous BMSCs transplantation",
                              "Genetic: Autologous EPCs transplantation",
                              "Genetic: IV infusion of placebo"
                        ],
                        "ArmGroupLabel": [
                              "BMSCs group",
                              "EPCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01468064"
                        ]
                  },
                  {
                        "Rank": 303,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients with relapsing remitting multiple sclerosis who receive cell free media",
                              "Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: injection of cell free media",
                              "Biological: intravenous injection of mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "cell free media",
                              "mesenchymal stem cell reciepiants"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01377870"
                        ]
                  },
                  {
                        "Rank": 304,
                        "Acronym": [
                              "ADMIRE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "injection of saline solution",
                              "hASC injection (1x10e6 / kg body weight)",
                              "injection of hASC (2x10e6 / kg of body weight)",
                              "injection of hASC (4x10e6 / kg body weight)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stromal Cells Injection",
                              "Biological: Stromal Cells Injection",
                              "Biological: Stromal Cells Injection",
                              "Biological: Stromal Cells Injection"
                        ],
                        "ArmGroupLabel": [
                              "PLACEBO GROUP",
                              "Low dose group",
                              "Intermediate Dose",
                              "High dose group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04005989"
                        ]
                  },
                  {
                        "Rank": 305,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: micro injection of SVF in vocal cords"
                        ],
                        "ArmGroupLabel": [
                              "micro injection of SVF in vocal cords"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02622464"
                        ]
                  },
                  {
                        "Rank": 306,
                        "Acronym": [
                              "METAGIST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03963544"
                        ]
                  },
                  {
                        "Rank": 307,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.",
                              "LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .",
                              "Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laparoscopic endoscopy combined surgery",
                              "Procedure: laparoscopic and endoscopic cooperative surgery",
                              "Procedure: Single-arch laparoscopic and endoscopic cooperative surgery"
                        ],
                        "ArmGroupLabel": [
                              "Laparoscopic surgery",
                              "laparoscopic and endoscopic",
                              "Single-arch laparoscopic and endoscopic"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02763748"
                        ]
                  },
                  {
                        "Rank": 308,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group is comprised by patients with diagnosis of resectable GISTs with/without liver metastasis. The patients included are na\u00efve (without previous treatment) or patients with stable/progressive disease following systemic therapy with tyrosine kinase inhibitors."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Endoscopic ultrasound guided radiofrequency ablation"
                        ],
                        "ArmGroupLabel": [
                              "EUS guided RFA"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05453292"
                        ]
                  },
                  {
                        "Rank": 309,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).\n\nSingle administration in addition to best standard medical care.",
                              "Best standard medical care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PLX-PAD"
                        ],
                        "ArmGroupLabel": [
                              "PLX-PAD Treatment",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04614025"
                        ]
                  },
                  {
                        "Rank": 310,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The subjects will apply exosome ointment along with Vesiderm liposome cream (TID per day, 20 days). Each day (from Day 1 to 20), the study product will be applied with a gap of 4 hours between three doses to a healthy area (one hand area) on the forearm using 1 fingertip unit (FTU). The Vesiderm liposome cream is meant to keep the application site moisturized."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Exosome ointment"
                        ],
                        "ArmGroupLabel": [
                              "Exosome Ointment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05523011"
                        ]
                  },
                  {
                        "Rank": 311,
                        "Acronym": [
                              "INV555"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: imatinib mesylate"
                        ],
                        "ArmGroupLabel": [
                              "imatinib mesylate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01172548"
                        ]
                  },
                  {
                        "Rank": 312,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement",
                              "SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Control group",
                              "Procedure: SVF group"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "SVF group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05270850"
                        ]
                  },
                  {
                        "Rank": 313,
                        "Acronym": [
                              "CELLCORDES2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery",
                              "Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ADSVF group",
                              "Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05385159"
                        ]
                  },
                  {
                        "Rank": 314,
                        "Acronym": [
                              "GIST"
                        ],
                        "AgreementOtherDetails": [
                              "The sponsor can review results communications prior to public release and can embargo communications regarding trial results for up to 1 year (to first generate a multicenter publication) and a period that is 60 to 120 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication to delete confidential information, excluding the results of the Study."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Participants with KIT exon 11-mutant GIST.",
                              "Participants with GIST that lack KIT exon 11 mutations (Cohort B)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Ponatinib",
                              "Drug: Ponatinib"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A",
                              "Cohort B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01874665"
                        ]
                  },
                  {
                        "Rank": 315,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients > 18 years of age",
                              "Patients < 18 years of age"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Selumetinib (AZD6244 hyd sulfate) 50mg/dose",
                              "Drug: Selumetinib (AZD6244 hyd sulfate) 25mg/m2"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1",
                              "Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03109301"
                        ]
                  },
                  {
                        "Rank": 316,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: total or subtotal gastrectomy"
                        ],
                        "ArmGroupLabel": [
                              "prognostic factors of gastrointestinal stromal tumors"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04269941"
                        ]
                  },
                  {
                        "Rank": 317,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01557543"
                        ]
                  },
                  {
                        "Rank": 318,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.",
                              "PLX-PAD 300, single administration, second administration of placebo after 1 week.",
                              "Placebo, two administrations, 1 week apart",
                              "PLX-PAD, single administration",
                              "Placebo, single administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PLX-PAD",
                              "Biological: PLX-PAD",
                              "Biological: Placebo",
                              "Biological: PLX-PAD",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "PLX-PAD interval high dose",
                              "PLX-PAD low dose",
                              "Control Group A",
                              "PLX-PAD high dose",
                              "Control Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04389450"
                        ]
                  },
                  {
                        "Rank": 319,
                        "Acronym": [
                              "BioMiStem-CT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)",
                              "The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)",
                              "The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration",
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration",
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration"
                        ],
                        "ArmGroupLabel": [
                              "MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity",
                              "Control Patients with type 2 diabetes and obesity",
                              "MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity",
                              "Control Patients without type 2 diabetes and with obesity",
                              "MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity",
                              "Control Patients without type 2 diabetes and without obesity"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05081921"
                        ]
                  },
                  {
                        "Rank": 320,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "collection of autologous SVF\nculture of SVF to abstain MSC\ninfusion of MSC during and after living-relative kidney transplantation",
                              "The control group will be inducted with Basiliximab"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: SVF-MSC induction",
                              "Drug: Basiliximab induction"
                        ],
                        "ArmGroupLabel": [
                              "SVF-MSC induction",
                              "Basiliximab induction"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02492308"
                        ]
                  },
                  {
                        "Rank": 321,
                        "Acronym": [
                              "ROBUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800\u00ae cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;",
                              "open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cellularized composite graft augmentation",
                              "Procedure: Acellular composite graft augmentation"
                        ],
                        "ArmGroupLabel": [
                              "cellularized composite graft augmentation",
                              "Control acellular composite graft augmentation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01532076"
                        ]
                  },
                  {
                        "Rank": 322,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Device: Echotip ProCore\u24c7 HD Ultrasound Biopsy Needle"
                        ],
                        "ArmGroupLabel": [
                              "Arm who will undergo EUS-FNB"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02884154"
                        ]
                  },
                  {
                        "Rank": 323,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCMSCs + CM is administered via intrathecal injection",
                              "UCMSCs is administered via intrathecal injection",
                              "Physiotherapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Other: Standard Therapy"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs + CM",
                              "UCMSCs",
                              "Standard Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314687"
                        ]
                  },
                  {
                        "Rank": 324,
                        "Acronym": [
                              "ASCAT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02064062"
                        ]
                  },
                  {
                        "Rank": 325,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: PLX-PAD IM injection",
                              "Biological: PLX-PAD IM injection",
                              "Biological: PLX-PAD IM injection"
                        ],
                        "ArmGroupLabel": [
                              "PLX-PAD low dose",
                              "PLX-PAD intermediate dose",
                              "PLX-PAD high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00919958"
                        ]
                  },
                  {
                        "Rank": 326,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "IM injection Single treatment; multiple injections",
                              "IM injection Double treatment; multiple injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PLX-PAD",
                              "Biological: PLX-PAD"
                        ],
                        "ArmGroupLabel": [
                              "PLX-PAD low dose",
                              "PLX-PAD high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00951210"
                        ]
                  }
            ]
      }
}